The proposed amendment does not specify that the approved medication be in the class known as GLP-1s, but GLP-1s like Ozempic, Wegovy and Zepbound have received significant media attention and are now in-demand by both practitioners and the public
Patient demand is shaping the market
If anything looks off, do not use it
Where the Gap in Prescribing Standards Is Most Acute The Medicare GLP-1 Bridge Program's eligibility criteria require a BMI of 27 or higher with at least one weight-related comorbidity, enrollment in Medicare Part D, and not currently using GLP-1 therapy for another covered indication
Then, if your blood sugar hasnt adequately improved after at least one week on the 0.6 mg dosage, your healthcare provider may increase your dose to 1.2 mg daily
Some actually perform worse